# THE PIRAMID STUDY : PATIENTS TREATED BY MYELOMA **ORAL MEDICATION HAVE A BAD COMPLIANCE**

N. Allaire, J.F. Huon, P. Nizet, C. Dubreuil, V. Burgeot, I. Rouiller, L. Flet, M. Tching-Sin CHU Nantes, Pharmacy, Nantes, France Abstract n°4CPS-139 ATC code: L04 - Immunosuppressive agents

# Background and purpose



Multiple myeloma is now treated by oral therapies, but their effectiveness depends on patient compliance. The Piramid study aimed to :

- assess patient medication compliance to myeloma oral treatments (Imids : Thalidomid, Lenalidomid, Pomalidomid) ;
- identify factors associated with medication compliance by adult outpatients.

# Material and methods




#### At a university teaching hospital

At the time of renewal dispensation

Prospective study

Were assessed	Using Using Usit 2018 Volt 2018
Medication compliance to Imids	Morisky (score /8)
Quality of life	SF-36 v1.3 (8 dimensions)
Satisfaction of treatment	SATMED-Q (score /100)
Health literacy	HLQ (9 dimensions)
Medical and sociodemographic data	Questionnaire (26 items)
Correlation between Morisky's compliance and other data : 47 items tested	Univariate analysis, Chi <sup>2</sup> and Wilcoxon tests

Results






#### Univariate analysis with Morisky's compliance score

### **Positive correlations**

Group « good

### Group « medium/bad



ltem	compliance » mean score	compliance » mean score	p
Satisfaction of treatment (SATMED-Q)	77.45	64.98	0.0081
Perceived health (SF- 36, Dimension 4)	50.93	35.34	0.0175
Psychic health (SF-36, dimension 7)	70.24	60.70	0.0119
Limitations associated to psychic health (SF- 36, dimension 8)	69.33	34.41	0.0047
Negative correla	ations		
ltem	Group « good compliance » % of yes	Group « medium/bad compliance » % of yes	þ
Existence of a tip to	7.14 %	30.30 %	0.0234



Being a member of a patients' association

remember drug intake

0.0	01	18	
•••			



#### **Problems**

Only half of the patients had an optimal compliance Easiest factors of bad compliance to measure : having a bad satisfaction of the treatment, being depressed

## **Solutions**?

- Therapeutic education
- Pharmaceutic interviews
  - Time is limited : focus patients with risk factors ?

